查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012772

抗肥胖处方药市场：依药物类别、给药途径、最终用户和通路划分－2026-2032年全球市场预测

Anti-obesity Prescription Drugs Market by Drug Class, Administration Route, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，抗肥胖处方药市场价值将达到 72.5 亿美元，到 2026 年将成长至 78.4 亿美元，到 2032 年将达到 127.7 亿美元，复合年增长率为 8.40%。

主要市场统计数据
基准年 2025 72.5亿美元
预计年份：2026年 78.4亿美元
预测年份 2032 127.7亿美元
复合年增长率 (%) 8.40%

简要概述正在改变处方笺抗减肥药和相关人员决策的临床、商业性和营运趋势。

在科学突破、新的给药方法以及支付方和政策制定者日益严格的审查的推动下，处方笺抗肥胖药物的治疗和商业性格局正经历着显着的变革时期。临床医生越来越多地将新的荷尔蒙疗法与对特定患者群体仍然有效的现有药物一起纳入治疗方案。同时，医疗设备的创新和新型口服製剂正在改变治疗方法和监测方式，为提高用药依从性和病人参与创造了新的干预点。

科学突破、管理方法创新和综合数位支援系统如何重新定义抗肥胖药物治疗的治疗策略和护理路径。

近年来，科学的进步已将药物治疗肥胖症的模式从症状治疗转变为基于机制和生理学的治疗方法，这些方法能够影响食慾调节、饱足信号传导和能量平衡。肠促胰岛素疗法的出现及其临床疗效加速了人们对多方面治疗方法和联合策略的兴趣，促使研发人员探索现有的胜肽类药物以及针对互补路径的新一代分子。因此，临床试验设计、终点选择和长期安全性监测均已发展演变，以反映人们对持续体重管理和心血管代谢效益的期望。

对近期美国关税措施对全球供应链、製造决策以及取得处方笺抗减肥药。

主要经济体的政策调整和关税措施可能会显着重塑复杂治疗药物的全球供应链和成本结构，尤其是在活性成分、生物製药原料和成品在生产过程中需要跨越多个国界的情况下。 2025年美国的关税环境为处方笺抗肥胖药物的筹资策略、契约製造关係和库存计画带来了新的考量。各公司正在重新评估供应商集中度带来的风险，并探索替代製造地，以减轻贸易政策变化的影响。

透过进行基于细分的详细分析，将药物类别、剂型、分销管道和最终用户环境联繫起来，我们可以製定准确的开发和商业化策略。

了解患者群体和产品剂型对于优化整个抗肥胖药物组合的临床开发、商业化和分销策略至关重要。药物类别包括Amylin类似物（如Pramlintide） 、一系列GLP-1促效剂（如Dulaglutide、Exenatide、Liraglutide和Semaglutide） 、以奥利司他为代表的脂肪酶抑制剂以及5-羟色胺受体调变器（如氯卡色林）。每个类别都具有独特的疗效、安全性和耐受性特征，这些特征指南药物的市场定位和处方医生的选择。此外，药物的使用模式也因製剂形式和给药途径而异。对于寻求长效或剂量可调治疗方法的患者和医护人员而言，自动注射器、预填充註射笔和传统的管瓶/注射器剂型更受欢迎。另一方面，口服胶囊和片剂为不愿注射的患者提供了更大的便利，并为基层医疗的应用提供了机会。

区域比较观点，突显美洲、欧洲、中东、非洲和亚太地区在监管预期、支付方趋势和分销方面的细微差异。

区域趋势正以独特的方式塑造着监管路径、支付方参与以及更广泛的临床实践生态系统。在美洲，监管机构和支付者正在仔细评估长期安全性和成本效益，而医疗服务提供者网路正在迅速采用整合药物治疗和行为介入的多模态护理模式。该地区的商业基础设施既支援专科诊所服务，也支持透过远端医疗扩大分销范围，从而促进了利用数位化用药依从性工具的灵活上市策略。

本报告透过公司概况和合作结构，揭示了整合开发、设备工程和数位伙伴关係如何创造竞争差异化和业务永续营运。

竞争格局涵盖传统製药企业、生物製剂专家、新兴生物技术创新者、医疗设备製造商、契约製造组织 (CMO) 和数位医疗供应商。在生物製剂开发、注射器器械工程和低温运输物流方面拥有综合能力的公司，在将肽类疗法推向市场时具有明显的商业优势。同时，灵活的生物技术公司正在开发新的作用机制和新製剂，并经常利用策略伙伴关係和许可授权来获得生产规模和商业基础设施。

为製药、製造和商业团队制定以行动为导向的策略重点，以协调证据产生、供应弹性和支付方伙伴关係，实现可持续的药物取得。

产业领导企业应优先考虑整合临床定位、生产韧性和支付方参与的整合策略，以保持竞争优势。首先，投资创建除对照临床试验之外的可靠安全性和真实世界数据 (RWE) 至关重要，这有助于支持保险覆盖范围谈判并证明患者的长期益处。在累积证据的同时，扩大医疗设备和製剂选择范围，可以透过满足不同的给药偏好和依从性需求来扩大目标患者群体。

对严谨、多方面的调查方法进行了透明的解释，该方法结合了临床文献回顾、专家访谈、生产评估和资料检验。

本研究采用多面向方法，结合同侪审查的临床文献、监管申报文件、指导文件和公共声明的系统性回顾，以及有针对性的初步研究。研究人员与内分泌科医生、基层医疗医生、监管专家、供应链高管、支付方和患者权益组织代表进行了专家咨询，以检验关键趋势和实际影响。在生产和物流评估方面，研究人员与契约製造製造商、医疗设备供应商和低温运输营运商进行了技术简报，以评估产能考量和风险缓解策略。

全面概述临床创新、供应韧性和支付方参与如何相互交织，从而决定抗减肥药的长期可及性和策略性成功。

处方笺抗减肥药的未来取决于科学创新、新的给药模式以及不断变化的政策和支付方期望，所有这些因素共同创造了机会，同时也带来了挑战。利用生理机制的新治疗方法正在促使人们重新思考长期管理策略，而给药方法和数位化支持的进步则拓宽了医疗服务和药物依从性支持工具的范围。同时，监管和采购趋势要求企业提供更强有力的真实世界数据（REW），并建立能够抵御地缘政治和贸易政策衝击的弹性供应链。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：抗肥胖处方药市场：依药物类别划分

  • Amylin类似物
    • Pramlintide
  • GLP-1促效剂
    • Dulaglutide
    • Exenatide
    • Liraglutide
    • Semaglutide
  • 脂肪酶抑制剂
    • 奥利司他
  • 血清素受体调变器
    • 氯卡色林

第九章：抗肥胖处方药市场：依给药途径划分

  • 注射药物
    • 自动注射器
    • 预填充笔
    • 管瓶和注射器
  • 口服药物
    • 胶囊
    • 药片

第十章：抗肥胖处方药市场：依最终用户划分

  • 门诊部
  • 居家照护设施
  • 医院
  • 专科诊所
    • 内分泌诊所
    • 全科诊所
    • 减重诊所

第十一章：抗肥胖处方药市场：依通路划分

  • 离线
  • 在线的

第十二章：抗肥胖处方药市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：抗肥胖处方药市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 抗肥胖处方药市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国：抗肥胖处方药市场

第十六章 中国：抗肥胖处方药市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Alizyme Limited
  • Amgen Inc.
  • AstraZeneca PLC
  • BioCon Limited
  • Boehringer Ingelheim International GmbH
  • CHEPLAPHARM Arzneimittel GmbH
  • Currax Pharmaceuticals LLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gelesis Holdings, Inc.
  • GlaxoSmithKline PLC
  • Hanmi Pharm.Co., Ltd.
  • HK inno.N Corporation
  • Innovent Biologics, Inc.
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Orexigen Therapeutics, Inc.
  • Pfizer Inc.
  • Reddy's Laboratories Limited
  • Rhythm Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals Company Limited
  • Verdiva Pharma Inc.
  • Vivus LLC
  • Zydus Lifesciences Limited
Product Code: MRR-4358BACA7FD1

The Anti-obesity Prescription Drugs Market was valued at USD 7.25 billion in 2025 and is projected to grow to USD 7.84 billion in 2026, with a CAGR of 8.40%, reaching USD 12.77 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.25 billion
Estimated Year [2026] USD 7.84 billion
Forecast Year [2032] USD 12.77 billion
CAGR (%) 8.40%

A concise orientation to the evolving clinical, commercial, and operational dynamics transforming prescription anti-obesity therapeutics and stakeholder decision-making

The therapeutic and commercial landscape for prescription anti-obesity drugs has entered a period of pronounced transformation driven by scientific breakthroughs, novel delivery formats, and intensified payer and policy scrutiny. Clinicians are increasingly integrating newer hormone-based agents into care pathways alongside legacy medications that continue to serve specific patient segments. Meanwhile, device innovations and novel oral formulations are changing how therapies are administered and monitored, creating fresh touchpoints for adherence interventions and patient engagement efforts.

Against this backdrop, stakeholders from biotech innovators to hospital systems must re-evaluate operational assumptions. Supply chains that were once linear are now subject to new sourcing requirements and capacity pressures, and the competitive environment is characterized by rapid product differentiation and strategic collaborations. The evolving interplay of clinical efficacy, tolerability profiles, and convenience is reshaping prescribing behavior and care delivery models, requiring cross-functional alignment between clinical development, regulatory affairs, commercial teams, and distribution partners.

How scientific breakthroughs, delivery innovations, and integrated digital support systems are collectively redefining therapeutic strategies and care pathways in anti-obesity pharmacotherapy

Recent scientific advances have shifted the paradigm of pharmacologic obesity management from symptomatic interventions to mechanistic, physiology-based approaches that impact appetite regulation, satiety signaling, and energy homeostasis. The emergence and clinical validation of incretin-based therapies have accelerated interest in multimodal regimens and combination strategies, prompting developers to explore both established peptide classes and next-generation molecules targeting complementary pathways. As a result, clinical trial design, endpoint selection, and long-term safety monitoring have all evolved to reflect expectations for sustained weight management and cardiometabolic benefit.

Concurrently, the realm of drug delivery and patient experience has seen meaningful innovation. Long-acting injectables, patient-friendly autoinjectors and prefilled pens, and improved oral formulations have reframed adherence conversations and enabled new points of care. Digital tools for adherence monitoring, remote titration, and behavioral support are increasingly integrated with pharmacotherapy, reinforcing therapeutic value through improved outcomes. Finally, market access and reimbursement dialogues now center on real-world effectiveness, health-economic evidence, and patient stratification, which together influence formulary placement and clinical adoption trajectories.

Assessment of the cascading operational consequences of recent United States tariff measures on global supply chains, manufacturing decisions, and access pathways for prescription anti-obesity therapeutics

Policy adjustments and tariff actions in major economies can materially reconfigure global supply chains and cost structures for complex therapeutics, particularly when active pharmaceutical ingredients, biologics manufacturing inputs, and finished-dose forms cross multiple borders during production. The 2025 tariff environment in the United States has introduced new considerations for sourcing strategies, contract manufacturing relationships, and inventory planning for prescription anti-obesity products. Companies are reassessing supplier concentration risks and exploring alternative manufacturing footprints to mitigate exposure to trade-policy volatility.

This recalibration has implications for manufacturing lead times, quality assurance oversight, and total landed costs, which in turn affect procurement strategies and the commercial calculus for entry into specific channels. In response, many stakeholders are pursuing dual-sourcing arrangements, nearshoring of critical processes, and renegotiation of commercial terms with logistics providers. Importantly, regulatory compliance and supply-chain traceability have become central to these efforts, as firms balance cost containment with the necessity of maintaining uninterrupted patient access to therapies across distribution networks.

Deep segmentation-driven analysis linking drug classes, administration formats, distribution channels, and end-user environments to inform precise development and commercialization tactics

Understanding patient segments and product modalities is essential to tailoring clinical development, commercialization, and distribution strategies across the anti-obesity portfolio. Drug classes span amylin analogs such as pramlintide, a range of GLP-1 agonists including dulaglutide, exenatide, liraglutide, and semaglutide, lipase inhibitors exemplified by orlistat, and serotonin receptor modulators like lorcaserin; each class presents distinct efficacy, safety, and tolerability profiles that inform positioning and prescriber choice. Moreover, formulation and administration route drive differential adoption patterns: injectables delivered via autoinjectors, prefilled pens, and traditional vial-and-syringe formats attract patients and providers seeking longer-acting or titratable therapies, while oral capsules and tablets offer convenience for those averse to injections and opportunities for primary care adoption.

Distribution channels and end-user settings further stratify opportunity and risk. Traditional offline channels remain important for clinical oversight, patient education, and cold-chain handling, while online pharmacies and telehealth-enabled dispensing expand access and convenience, particularly for chronic management. End users range from ambulatory care centers and hospitals to home-care settings and specialty clinics; within specialty clinics, endocrinology practices, general practice clinics, and weight-loss clinics each demand tailored support, educational materials, and clinical protocols. Therefore, commercialization strategies must be nuanced, aligning product attributes with administration preferences, channel dynamics, and the specific needs of prescriber types and care settings.

Comparative regional perspectives highlighting regulatory expectations, payer dynamics, and distribution nuances across the Americas; Europe, Middle East & Africa; and Asia-Pacific territories

Regional dynamics shape regulatory pathways, payor interactions, and the broader ecosystem of clinical practice in distinctive ways. In the Americas, regulatory agencies and payers are closely evaluating long-term safety and cost effectiveness, while provider networks are rapidly adopting multimodal care models that integrate pharmacotherapy with behavioral interventions. The commercial infrastructure in this region supports both specialty clinic delivery and expanding telehealth-enabled distribution, encouraging flexible launch strategies that leverage digital adherence tools.

Europe, the Middle East & Africa present heterogeneous regulatory and reimbursement landscapes that require localized evidence generation and engagement approaches. Many countries emphasize rigorous health-economic assessments and comparative effectiveness data, which influences pricing negotiations and formulary access. In this region, partnerships with regional distributors and specialized clinics are often essential to navigate fragmented delivery channels. Asia-Pacific markets exhibit diverse maturity levels; some countries are advancing rapid uptake of cutting-edge therapies supported by integrated hospital systems and strong manufacturing capabilities, while others are prioritizing cost containment and domestic production. Supply-chain resilience, regulatory harmonization efforts, and culturally adapted patient-support programs are therefore critical considerations across these geographies.

Strategic company profiles and alliance architectures that reveal how integrated development, device engineering, and digital partnerships are shaping competitive differentiation and operational resilience

The competitive landscape encompasses legacy pharmaceutical manufacturers, biologics specialists, emerging biotech innovators, device makers, contract manufacturing organizations, and digital health vendors. Firms with integrated capabilities across biologics development, device engineering for injectables, and cold-chain logistics possess distinct operational advantages when bringing peptide-based therapies to market. Simultaneously, agile biotech companies are advancing novel mechanisms of action and new formulations, often leveraging strategic partnerships or licensing deals to access manufacturing scale and commercial infrastructure.

Supply-chain and contract manufacturing partners are increasingly visible as pivotal contributors to product availability and cost efficiency. Device manufacturers that can deliver patient-centered autoinjectors and user-friendly pens enhance adherence and support provider uptake. Digital therapeutics vendors offering behavioral coaching, remote titration, and adherence analytics are becoming important adjuncts to pharmacotherapy, enabling value demonstrations to payers and providers. Across the sector, collaborative models-ranging from co-development agreements to distribution partnerships-are central to de-risking launches and accelerating time to patient access.

Action-oriented strategic priorities for pharmaceutical, manufacturing, and commercial teams to align evidence generation, supply resilience, and payer partnerships for sustained access

Industry leaders should prioritize integrated strategies that align clinical positioning, manufacturing resilience, and payer engagement to sustain competitive advantage. First, investing in robust safety and real-world evidence generation that extends beyond controlled trials will be essential to support coverage conversations and demonstrate long-term patient benefit. Parallel to evidence generation, expanding device and formulation options can broaden the addressable patient base by meeting diverse administration preferences and adherence needs.

Operationally, diversifying supply-chain footprints via geographically distributed manufacturing, strategic contract manufacturing partnerships, and enhanced raw-material traceability will reduce exposure to policy shocks and capacity constraints. Commercial teams should deploy channel-specific approaches that integrate in-clinic initiation protocols with telehealth follow-up and digital adherence supports to optimize continuity of care. Finally, pursuing selective collaborations with payers and health systems to develop outcomes-based contracts or risk-sharing agreements can facilitate access while aligning incentives around measurable clinical outcomes and cost offsets.

Transparent description of the rigorous multi-method research approach combining clinical literature review, expert interviews, manufacturing assessments, and data triangulation

This research synthesizes a multi-method approach combining a structured review of peer-reviewed clinical literature, regulatory filings, guidance documents, and public policy statements with targeted primary research. Expert consultations were conducted with clinicians across endocrinology and primary care, regulatory specialists, supply-chain executives, payers, and patient advocacy representatives to validate key trends and operational implications. Manufacturing and logistics assessments drew on technical briefings with contract manufacturers, device suppliers, and cold-chain providers to assess capacity considerations and mitigation strategies.

Data triangulation and cross-validation techniques were used to reconcile qualitative insights with publicly available clinical and regulatory information. The study applied segmentation mapping to align drug-class attributes with delivery modalities, channel dynamics, and end-user needs. Quality assurance protocols included peer review by subject-matter experts, consistency checks across regional assessments, and verification of factual statements against authoritative regulatory documents. Ethical considerations and confidentiality safeguards were maintained for all primary interviews and proprietary inputs.

A synthesized closing perspective on how clinical innovation, supply resilience, and payer engagement converge to determine long-term access and strategic success in anti-obesity therapeutics

The trajectory of prescription anti-obesity therapeutics is defined by scientific innovation, new delivery models, and shifting policy and payer expectations that together create both opportunity and complexity. Emerging therapies that leverage physiologic mechanisms have catalyzed rethinking of long-term management strategies, while advances in administration and digital support expand the spectrum of care settings and adherence tools. At the same time, regulatory scrutiny and procurement dynamics are compelling firms to produce stronger real-world evidence and to design resilient supply chains that can withstand geopolitical and trade-policy disruptions.

Decision-makers must therefore adopt integrated playbooks that bring clinical evidence, manufacturing strategy, and commercial execution into alignment. By doing so, organizations can better match product attributes to patient needs, secure reliable access across channels and geographies, and demonstrate value to payers and providers. The coming years will reward stakeholders who combine clinical credibility with operational agility and partnership-driven commercialization, enabling sustainable patient access to effective anti-obesity pharmacotherapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-obesity Prescription Drugs Market, by Drug Class

  • 8.1. Amylin Analogs
    • 8.1.1. Pramlintide
  • 8.2. GLP-1 Agonists
    • 8.2.1. Dulaglutide
    • 8.2.2. Exenatide
    • 8.2.3. Liraglutide
    • 8.2.4. Semaglutide
  • 8.3. Lipase Inhibitors
    • 8.3.1. Orlistat
  • 8.4. Serotonin Receptor Modulators
    • 8.4.1. Lorcaserin

9. Anti-obesity Prescription Drugs Market, by Administration Route

  • 9.1. Injectables
    • 9.1.1. Auto-Injectors
    • 9.1.2. Prefilled Pens
    • 9.1.3. Vials And Syringes
  • 9.2. Orals
    • 9.2.1. Capsules
    • 9.2.2. Tablets

10. Anti-obesity Prescription Drugs Market, by End User

  • 10.1. Ambulatory Care Centers
  • 10.2. Home Care Settings
  • 10.3. Hospitals
  • 10.4. Specialty Clinics
    • 10.4.1. Endocrinology Clinics
    • 10.4.2. General Practice Clinics
    • 10.4.3. Weight Loss Clinics

11. Anti-obesity Prescription Drugs Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Anti-obesity Prescription Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Anti-obesity Prescription Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Anti-obesity Prescription Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Anti-obesity Prescription Drugs Market

16. China Anti-obesity Prescription Drugs Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Alizyme Limited
  • 17.6. Amgen Inc.
  • 17.7. AstraZeneca PLC
  • 17.8. BioCon Limited
  • 17.9. Boehringer Ingelheim International GmbH
  • 17.10. CHEPLAPHARM Arzneimittel GmbH
  • 17.11. Currax Pharmaceuticals LLC
  • 17.12. Eli Lilly and Company
  • 17.13. F. Hoffmann-La Roche Ltd.
  • 17.14. Gelesis Holdings, Inc.
  • 17.15. GlaxoSmithKline PLC
  • 17.16. Hanmi Pharm.Co., Ltd.
  • 17.17. HK inno.N Corporation
  • 17.18. Innovent Biologics, Inc.
  • 17.19. Merck & Co., Inc.
  • 17.20. Novo Nordisk A/S
  • 17.21. Orexigen Therapeutics, Inc.
  • 17.22. Pfizer Inc.
  • 17.23. Reddy's Laboratories Limited
  • 17.24. Rhythm Pharmaceuticals, Inc.
  • 17.25. Takeda Pharmaceutical Company Limited
  • 17.26. Teva Pharmaceuticals Company Limited
  • 17.27. Verdiva Pharma Inc.
  • 17.28. Vivus LLC
  • 17.29. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PRAMLINTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PRAMLINTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PRAMLINTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DULAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DULAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY EXENATIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY EXENATIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY EXENATIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LOCASERIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LOCASERIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LOCASERIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AUTO-INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AUTO-INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AUTO-INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PREFILLED PENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PREFILLED PENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PREFILLED PENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY VIALS AND SYRINGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY VIALS AND SYRINGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY VIALS AND SYRINGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ENDOCRINOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ENDOCRINOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ENDOCRINOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY WEIGHT LOSS CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY WEIGHT LOSS CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY WEIGHT LOSS CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 206. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 207. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 208. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 209. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 211. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 212. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 213. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 215. GCC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 242. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 243. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 244. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 245. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 246. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 247. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 248. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 249. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 251. G7 ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 254. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 255. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 256. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 257. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 258. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 259. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 260. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 261. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 263. NATO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AMYLIN ANALOGS, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY GLP-1 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIPASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORALS, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)